Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Fludarabine and Alemtuzumab Refractory B-CLL
NCT00349349Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Primary completion
- May 2008
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by GSK. Started Jun 2006; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00349349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349349.